Zenara Pharma receives CDSCO approval to manufacture Pfizer’s Covid drug

Hyderabad, July 28: Hyderabad-based Zenara Pharma, a fully owned subsidiary of Biophore India Pharmaceuticals, on Thursday announced that it has received approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market Nirmatrelvir and Ritonavir tablets in a combi pack as a treatment option for patients with mild to moderate symptoms of Covid-19.
The tablet, which will be sold under the brand name ‘Paxzen’, is being manufactured at Zenara’s US FDA approved state-of-the-art facility in Hyderabad, the Pharma company said in a release here.
This approval by the CDSCO has been granted under the emergency authorization route considering the unmet medical need in COVID-19 for an effective and affordable therapy for the patients in India.
Dr Jagadeesh Babu Rangisetty, Co-founder and Managing Director at Zenara Pharma, said We believe Paxzen is an extremely effective treatment option against COVID-19 and, at the same time, is a very complex product to develop and manufacture.
We have brought this product to the market in record time and this is one of the first approvals of this product in India. We have our own in-house API and are not dependent on any imports for the production. We believe that this will ensure stability and rapid production and availability of this treatment for the Indian market, he said.
This product’s breakthrough approval in the US was given by the US FDA in December 2021 and is indicated for the treatment of mild-to-moderate COVID-19 in adults.
It was the first oral pill that has been approved by the US FDA and with a better safety profile than subsequently approved oral therapies.
Dr Srinivas Arutla, CEO, Zenara Pharma, said. We expect to launch Paxzen in the next couple of weeks and are in talks with multiple institutions and several hospitals in India to ensure that the product is readily available for patients in need.
We are also likely to tie up with other partners across the country to increase patient coverage and have been inviting discussions on the same, Dr Arutla added. (UNI)